Paradise Genomics focuses on the acquisition of highly qualified clinical samples, which are used to discover unique gene expression signatures in either blood or tissue. These biomarkers differentiate health from disease, and are indicative of the stage and progression of a disease.
The core strength and sole focus of Paradise Genomics, Inc. is biomarker discovery using whole-genome expression measurements. We utilize a proprietary technology platform and process developed through our founders’ combined 50+ years of experience in gene expression and analysis. This process has significant advantages in cost, discovery rate, and sensitivity and provides highly sensitive and reproducible results. Paradise Genomics provides unmatched high performance gene expression metrics for sensitivity, dynamic range, and reproducibility from extremely small amounts of sample material.
Paradise Genomics’ gene expression signatures contain previously undiscoverable biomarkers.
These proprietary disease biomarkers are marketed for commercialization to strategic partners with established product and distribution systems. These partners are primarily pharmaceutical, biotechnology, and medical diagnostic companies with applications in diagnostics, prognostics, therapeutic monitoring, and orphan drug discovery.
Paradise Genomics’ gene expression signatures contain previously undiscoverable biomarkers. These biomarkers provide new drug discovery targets and companion diagnostic indicators of drug efficacy that conventional technologies have not been able to produce.
This is the Paradise Advantage.